Patients with a documented history of chronic pancreatitis or more than one episode of acute pancreatitis should not use GLP-1 agents outside of a setting where a gastroenterologist is involved in the treatment plan
Moreover, several case studies have reported improvements in muscle function and well-being in people with this disorder (21, 22)

Patients who might be considered for GLP-1 therapy (within licensed indications) and who may experience secondary benefits for binge eating behaviours include: Individuals with binge eating disorder and type 2 diabetes , where GLP-1 agonists address the primary diabetes indication whilst potentially helping with eating patterns Those with BED and obesity who meet NHS eligibility criteria for weight management medications (as defined by NICE TA875 for semaglutide or TA664 for liraglutide, which are narrower than the marketing authorisation) Patients who have not responded adequately to psychological interventions such as cognitive behavioural therapy (CBT) and who have concurrent metabolic conditions Those experiencing significant food cravings and loss-of-control eating as part of their weight management challenges However, important cautions and considerations apply

As a result, the expected cost is typically higher than for online research-grade products, often 23 times as much, depending on quality and source
NOTE: If you have a medical condition, or taking medications, consult your healthcare professional before using this product
"But for women who have insulin resistance, once they treat the metabolic pathways that have been dysregulated because of obesity and because of insulin resistance, women can actually improve their fertility whether they realize it or not." Saunders said whether a GLP-1 medication may improve fertility depends on a woman's individual medical condition and should be discussed with her health care provider